Abivax: ABX464 inhibits replication of SARS-CoV-2 (COVID-19) in reconstituted human respiratory epithelium model
- Written by Reporters
ABX464 is the only drug candidate with a potential triple action for COVID-19 treatment: antiviral, anti-inflammatory and tissue repair
- ABX464, as assessed by RTqPCR, inhibits in vitro viral replication of SARS-CoV-2 (COVID-19)
- Simultaneously, Abivax receives ANSM and CPP clearance[1] to test ABX464 as promising COVID-19 therapeutic candidate...